Leading the Future of Oncology
Discover how The START Center for Cancer Research is revolutionizing cancer care with our global network of early phase oncology sites.
Pharma
Harnessing START's Expertise for Breakthrough Therapies
Our mission is to bridge the gap between innovative therapies and patients in the community setting, ensuring accessible and effective treatments for all.
About The START Center For Cancer Research
The START Center for Cancer Research is the world’s only global fully dedicated community-based early phase research organization. With eight locations in the United States and Europe, we have an established track record of success with leading biopharma sponsors and CROs. Most notably, 95% of the time, we are the first site to open across the studies that we work on, making us a top enroller and historically the first site to dose patients.
Experienced medical oncologists across all cancer types
Completed and active studies in our company’s history
FDA/EMA approved therapies our team has participated in
START locations in the United States and Europe
Patients enrolled in our clinical trials
New patients per year at START locations
A snapshot of commercially approved therapies we contributed to
Our Expertise
Our Expertise Spans Across all Cancer Areas, Most Notably In:
Bladder Cancer
Kidney Cancer
Breast Cancer
Leukemia
Gastro / Colon Cancer
Lung Cancer
Genitourinary / Gynecological Cancer
Lymphoma
Neourological Cancer
Pancreatic
Prostate Cancer
Skin Cancer
Serving Global Communities
Expanding Access to Clinical Trials
We specialize in accelerating and expanding access to clinical trials through our highly differentiated community-based research solutions.
At The START Center for Cancer Research, we recognize the importance of health equity and community impact in cancer care. Currently, 80% of cancer patients are treated in community settings, but they only have access to 20% of cancer trials. On the other hand, academic medical centers (AMCs) see 20% of patients but give their patients access to 80% of trials. This disparity must change.
Early phase oncology trials are the fastest growing segment in drug development, with a 50% growth rate in the past five years. However, there are significant challenges in conducting these trials, including long study activation timelines, lack of diversity in patient enrollment, soaring competition, and limited access to patients in community settings.
Partner with Start
Partnering With The START Center for Cancer Research for Advanced Innovation
We address the biggest pain points in clinical trials for sponsors by offering a fully dedicated community-based early phase research organization. Our unique approach includes embedding AMC-grade investigators in community practices and hospitals, expanding site capacity, and providing transparent and reliable enrollment performance. With our extensive network of community oncology practices and hospitals globally, we offer access to highly diverse patient populations, with over 30,000 new patients per year.
By partnering with START, pharmaceutical companies can benefit from our integrated community oncology network of sites, access to global community-based cancer populations, and our track record of successful enrollment in early phase trials. We offer rapid contract and budget negotiation, accelerated study startup, and a fully managed network of early phase units with centralized support services.
The Start Difference
START Is 100% Dedicated to Early Phase Research
- Highly focused on early phase oncology
- Highly tenured PIs with deep early phase experience
- Fully global with expanding global presence
- Rapid contract/budget and startup
- Fully managed network of early phase units
- Centralized support services
- Staffed with START employees
Let's Talk
Join Us in Accelerating Cancer Research and Treatments
Together, we can accelerate the speed and impact of early phase oncology trials, bringing innovative therapies to patients in need. Contact us today to learn more about how we can work together to advance cancer research and improve patient outcomes.
